Search Articles

View query in Help articles search

Search Results (1 to 10 of 10 Results)

Download search results: CSV END BibTex RIS


Design and Implementation of a Dashboard for Drug Interactions Mediated by Cytochromes Using a Health Care Data Warehouse in a University Hospital Center: Development Study

Design and Implementation of a Dashboard for Drug Interactions Mediated by Cytochromes Using a Health Care Data Warehouse in a University Hospital Center: Development Study

In cases of overdosing, adverse drug effects can be exacerbated. A recent study was conducted by the pharmacology department regarding the prescription of clopidogrel and CYP450 2 C19 genotyping. Clopidogrel is an antiplatelet agent and a prodrug, meaning it needs to undergo hepatic transformation to become an active substance that will be effective. This transformation or metabolism is carried out by the CYP450 2 C19 enzyme.

Laura Gosselin, Alexandre Maes, Kevin Eyer, Badisse Dahamna, Flavien Disson, Stefan Darmoni, Julien Wils, Julien Grosjean

JMIR Med Inform 2024;12:e57705

Automated System to Capture Patient Symptoms From Multitype Japanese Clinical Texts: Retrospective Study

Automated System to Capture Patient Symptoms From Multitype Japanese Clinical Texts: Retrospective Study

Processing large amounts of data using artificial intelligence can help to rapidly obtain a comprehensive understanding of the patient status, which can potentially streamline medical studies focusing on patient stratification, drug safety, and adverse drug event (ADE) detection. Particularly, information on ADEs must be collected prospectively, which is expensive and time-consuming.

Tomohiro Nishiyama, Ayane Yamaguchi, Peitao Han, Lis Weiji Kanashiro Pereira, Yuka Otsuki, Gabriel Herman Bernardim Andrade, Noriko Kudo, Shuntaro Yada, Shoko Wakamiya, Eiji Aramaki, Masahiro Takada, Masakazu Toi

JMIR Med Inform 2024;12:e58977

Online Delivery of Interprofessional Adverse Childhood Experiences Training to Rural Providers: Usability Study

Online Delivery of Interprofessional Adverse Childhood Experiences Training to Rural Providers: Usability Study

A large proportion of providers are unaware of the detrimental effects of adverse childhood experiences (ACEs) [1]. ACEs are commonly defined as personal abuse that is psychological, physical, or sexual; personal neglect that is emotional or physical; or household challenges that include violence against the mother, divorce, or separation; or living with household members who were substance abusers, mentally ill or suicidal, or had ever been imprisoned [2,3].

Julie M Kapp, Rachel Dicke, Kathleen Quinn

JMIR Pediatr Parent 2024;7:e56722

Ischemic Stroke After Bivalent COVID-19 Vaccination: Self-Controlled Case Series Study

Ischemic Stroke After Bivalent COVID-19 Vaccination: Self-Controlled Case Series Study

To monitor safety postlicensure, a study using V-safe and the Vaccine Adverse Event Reporting System (VAERS) examined bivalent booster vaccinations in individuals aged older than or equal to 12 years and found that the safety profile was similar to that described for monovalent booster vaccinations [6].

Stanley Xu, Lina S Sy, Vennis Hong, Kimberly J Holmquist, Lei Qian, Paddy Farrington, Katia J Bruxvoort, Nicola P Klein, Bruce Fireman, Bing Han, Bruno J Lewin

JMIR Public Health Surveill 2024;10:e53807

Impact of Electronic Patient-Reported Outcomes on Unplanned Consultations and Hospitalizations in Patients With Cancer Undergoing Systemic Therapy: Results of a Patient-Reported Outcome Study Compared With Matched Retrospective Data

Impact of Electronic Patient-Reported Outcomes on Unplanned Consultations and Hospitalizations in Patients With Cancer Undergoing Systemic Therapy: Results of a Patient-Reported Outcome Study Compared With Matched Retrospective Data

It can be assumed that by structured recording of patient reported symptoms, adverse events of cancer therapy can be recognized at an early stage and higher degrees of severity can be avoided through timely action. This is supported by recent studies. It was shown that the use of a digital app or web-based system for symptom monitoring had reduced the number of emergency admissions and hospitalizations compared to a control group and had even extended (progression-free) survival times [8-11].

Andreas Trojan, Christian Kühne, Michael Kiessling, Johannes Schumacher, Stefan Dröse, Christian Singer, Christian Jackisch, Christoph Thomssen, Gerd A Kullak-Ublick

JMIR Form Res 2024;8:e55917

Peer Review for “Thyroid Hyperplasia and Neoplasm Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists in the Food and Drug Administration Adverse Event Reporting System: Retrospective Analysis”

Peer Review for “Thyroid Hyperplasia and Neoplasm Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists in the Food and Drug Administration Adverse Event Reporting System: Retrospective Analysis”

This is the peer-review report for “Thyroid Hyperplasia and Neoplasm Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists in the Food and Drug Administration Adverse Event Reporting System: Retrospective Analysis.”

Anonymous

JMIRx Med 2024;5:e59120

Authors’ Response to Peer Reviews of “Thyroid Hyperplasia and Neoplasm Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists in the Food and Drug Administration Adverse Event Reporting System: Retrospective Analysis”

Authors’ Response to Peer Reviews of “Thyroid Hyperplasia and Neoplasm Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists in the Food and Drug Administration Adverse Event Reporting System: Retrospective Analysis”

This is the authors’ response to peer-review reports for “Thyroid Hyperplasia and Neoplasm Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists in the Food and Drug Administration Adverse Event Reporting System: Retrospective Analysis.”

Tigran Makunts, Haroutyun Joulfayan, Ruben Abagyan

JMIRx Med 2024;5:e58273

Thyroid Hyperplasia and Neoplasm Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists in the Food and Drug Administration Adverse Event Reporting System: Retrospective Analysis

Thyroid Hyperplasia and Neoplasm Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists in the Food and Drug Administration Adverse Event Reporting System: Retrospective Analysis

Common adverse events (AEs) associated with GLP-1 RAs observed during the clinical trials include nausea, hypoglycemia, vomiting, diarrhea, feeling jittery, dizziness, headache, and dyspepsia. Of a greater concern are the labeled boxed warnings of liraglutide, semaglutide, and dulaglutide, marking these as contraindicated in patients with a family history of medullary thyroid carcinoma.

Tigran Makunts, Haroutyun Joulfayan, Ruben Abagyan

JMIRx Med 2024;5:e55976